Influence of Angiotensin-Converting-Enzyme Gene Polymorphism on Echocardiographic Data of Patients with Ischemic

Related Experiment Video

Updated: Mar 12, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

20.1K

Gustavo Salgado Duque1, Dayse Aparecida da Silva2, Felipe Neves de Albuquerque1

  • 1Hospital Universitário Pedro Ernesto - Universidade Estadual do Rio de Janeiro (UERJ); RJ - Brazil.

Arquivos Brasileiros De Cardiologia
|November 5, 2016
PubMed

Insights

The angiotensin-converting-enzyme (ACE) I/D polymorphism influences outcomes in patients with ischemic heart failure. DD genotype carriers showed worse echocardiographic results, while II genotype carriers had better outcomes, highlighting genetic associations in cardiovascular disease.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Heart Failure Pathophysiology

Background:

  • The association between angiotensin-converting-enzyme (ACE) gene polymorphisms and clinical/echocardiographic outcomes in heart failure (HF) and coronary artery disease is established.
  • Investigating the genetic profile of local populations with these conditions is crucial for understanding disease associations.

Purpose of the Study:

  • To determine the frequency of ACE gene polymorphisms in ischemic heart failure patients from Rio de Janeiro.
  • To analyze the association between ACE gene polymorphisms and echocardiographic findings in this population.

Main Methods:

  • Genetic analysis of the I/D ACE polymorphism was performed.
  • Clinical, laboratory, and echocardiographic data were collected from 99 patients.
  • Statistical analysis correlated ACE genotypes with echocardiographic parameters.

Main Results:

  • Allele frequencies: 53 I, 145 D. Genotype frequencies: DD (49.5%), DI (47.48%), II (3.02%).
  • Patients with DD genotype showed a higher worsening in left ventricular ejection fraction (LVEF), LV systolic diameter (LVSD), and LV diastolic diameter (LVDD) compared to DI and II genotypes.
  • The II genotype was associated with the best echocardiographic outcomes, particularly in ΔLVDD.

Conclusions:

  • The DD genotype in ACE gene polymorphisms is linked to worse echocardiographic progression in ischemic heart failure patients.
  • The II genotype appears to be associated with a more favorable echocardiographic outcome.
  • These findings underscore the importance of genetic profiling in managing heart failure patients.
Abstract

More Related Videos

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

4.9K
Assessment of Cardiac Morphological and Functional Changes in Mouse Model of Transverse Aortic Constriction by Echocardiographic Imaging09:05

Assessment of Cardiac Morphological and Functional Changes in Mouse Model of Transverse Aortic Constriction by Echocardiographic Imaging

Published on: June 21, 2016

19.1K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
607